CorMedix (NASDAQ: CRMD) CEO buys 80,000 shares in latest insider filing

What happened

CorMedix CEO Joseph Todisco bought 80,000 shares of CorMedix Inc. (NASDAQ: CRMD), lifting his direct stake in the company's common stock. The purchase matters because it adds to the CEO's direct ownership and gives holders a current read on how much stock he kept personally.

Todisco's Form 4 says the purchase happened on Nov. 13, and he signed the report on Nov. 16, after the trades were done. The filing lists him as a director, chief executive officer and 10% owner, and it shows common stock rather than derivative securities. After the purchase, he held 854,749 shares directly.

Key numbers

Metric Latest Change Source
Common shares bought 80,000 shares SEC Form 4
Weighted average price $4.89 SEC Form 4
Purchase value about $391,200 SEC Form 4
Shares held after trade 854,749 shares SEC Form 4
Purchase as share of pre-trade holding 10.3% Calculated from SEC Form 4

Read more: CorMedix (CRMD) company research

Why it matters

He paid a weighted average $4.89 a share, and the transaction was about $391,200 in total across the reported fills. The report says the shares changed hands in multiple trades at prices from $4.85 to $5.00, so the weighted average is the cleanest single price.

OptimistFi has argued that CorMedix can become a profitable, cash-generating specialty pharmaceutical company by combining DefenCath's unique dialysis-market position with Melinta's hospital-focused infectious-disease portfolio. Todisco's buy strengthens that view slightly because the CEO added to his stake, and holders can see that commitment in direct ownership.

The purchase equals about 10.3% of Todisco's pre-trade holding of 774,749 shares, which makes it a meaningful addition to his own exposure. That makes the buy more than a token fill, but it is still only one transaction and a narrow signal for investors. The best caveat is that the filing condenses multiple fills into one weighted average, so investors should read it as a narrow ownership signal.

For holders, that makes the filing useful as a clean ownership update and a straightforward read on the CEO's stake.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

CorMedix's next quarterly report is the next observable check on whether the company backs this insider move with business progress. A stronger report would make the purchase look more in step with management's outlook, while a weaker one would leave it as a standalone buy.

More from OptimistFi

From OptimistFi Perps

Sources

  • SEC Form 4 — Joseph Todisco reported a purchase of CorMedix common stock on Nov. 13, 2026, executed in multiple trades at $4.85 to $5.00.

Explore OptimistFi research on CorMedix Inc.: https://optimistfi.com/stocks/CRMD

Browse CorMedix Inc. company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the CorMedix Inc. company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.